Title: Study of Lipid Profile in Chronic Kidney Disease Patients of Non Diabetic Etiology and its Relation to Serum Calcium

Authors: Dr Jose Kunnel Paul, Dr Sheela Kurian V

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i9.153

{tab Abstract}

Background: Patients suffering from chronic kidney disease are prone to develop diseases related to the cardiovascular system owing to the accelerated rate of atherosclerosis due to a multitude of factors, one of them being the characteristic "atherogenic" lipid profile abnormality that they exhibit. Few studies have pointed out the role of secondary hyperparathyroidism as a contributing factor in the development of the abnormal lipid profile.

Aim

1. To study the pattern of lipid profile abnormalities in chronic kidney disease patients of non-diabetic aetiology and to assess the relation between the degree of renal impairment and the extent of alteration of lipid profile.
2. To study the association between the serum calcium and phophorous levels and hypertriglyceridemia.

Materials and Methods: 150 patients were carefully selected after assessing their eligibility using the inclusion and exclusion criteria. History, clinical examination and biochemical investigations were performed .Blood for the assessment of lipid profile was collected after a minimum of 9 hours fasting and a light fat free diet on the previous day. Data was analysed using SPSS software.

Results: Patients with chronic kidney disease were likelier to have higher levels of triglyceride and lower HDL values and as the stage of CKD progressed, the abnormalities in TGL and HDL values increased. There is a positive correlation between the level of triglycerides and serum phosphorous in both stage 4 and 5 CKD and an inverse correlation between serum TGL and calcium in stage 4.Dialysed patients exhibit no alteration in their lipid profile as compared to non dialysed patients.

Keywords: Lipid Profile, Chronic Kidney Disease, Non-Diabetic Etiology, Calcium.

{tab References}

1. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease.Am J Nephrol. 2004 Jan-Feb;24(l):46-53.
2. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003 May;63(5): 1964-76.
3. Hyperlipidemia in patients with chronic renal disease.Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S142-56.
4. Solakivi T, Jaakkola O, Salomaki A, Peltonen N, Metso S, Lehtimaki T, Nikkari ST. HDL enhances oxidation of LDL in vitro in both men and women.Lipids Health Dis. 2005 Oct 20;4:25.
5. Moore KJ, Freeman MW.Scavenger receptors in atherosclerosis: Beyond lipid uptake.ArteriosclerThrombVase Biol. 2006 Aug;26(8): 1702-11.
6. MajumdarArghya, David C Wheeler.Lipid abnormalities in renal disease.J R Soc Med. 2000 Apr;93(4): 178-82.
7. Senti M, Romero R, Pedro-Botet J, et al. Lipoprotein abnormalities in hyperlipi-demic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int. 1992 May;41(5):1394-9.
8. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure Am J Kidney Dis. 1993 Jun;21(6):573-92.
9. Arnadottir M, Thysell H, Dallongeville J, et al. Evidence that reduced lipoprotein lipase activity is not a primary pathogen-netic factor for hypertriglyceridemia in renal failure Kidney Int. 1995 Sep;48(3):779-84.
10. Liang K, Oveisi F, Vaziri ND. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int. 1998 Mar;53(3):626-30.
11. Lacour B, Roullet JB, Liagre AM, et al. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis. 1986 Dec;8(6):422-9.
12. Akmal M, Perkins S, Kasim SE, et al. Verapamil prevents chronic renal failure- induced abnormalities in lipid metabolism. Am J Kidney Dis. 1993 Jul;22(l): 158-63.
13. Navarro JF1, Teruel JL, Lasuncion MA, Mora-Fernandez C, OrtunoJ.Relationship between serum parathyroid hormone levels and lipid profile in hemodialysis patients. Evolution of lipid parameters after parathyroidectomy. Clin Nephrol. 1998 May;49(5):303-7.
14. Ahmadi Fl, Miijafari SR, Khatami Mr, Khazaeipour Z, Ranjbarnovin N. Relationship between serum parathyroid hormone levels and lipid profile in non-diabetic hemodialysispatients.Saudi J Kidney Dis Transpl. 2012 Nov;23(6): 1188-95. doi: 10.4103/1319-2442.
15. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int. 1996 May;49(5): 1360-71.
16. Kuboyama M, Ageta M, Ishihara T, et al. Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. J Atheroscler Thromb. 2003;10(5):283-9
17. Wheeler DC. "Should hyperlipidemia in dialysis patients be treated?".Nephrol Dial Transplant. 1997 Jan; 12(1): 19-21.
18. Attman P.O; Samuelsson O. Dyslipidaemia of Kidney disease. Curr Open Lipidol. 2009 Aug : 20 (4) : 293 -9
19. Vaziri ND, Moradi H ; Mechanisms of dyslipidaemia of chronic renal failure. Haemodial. Int. 2006 Jan ; 10(1)1-7.
20. Attman PO ; Samuelsson.O, Johansson AC, Moberly JB, And Alaupovic P. Dialysis modalities and dyslipidaemias. Kidney Int Suppl. 2003 may ; (84) : S 110 -112
21. Deighan CJ, Caslake MJ, Mc Connell M, Boulton – Jones JM, and Packard CJ. Atherogenic lipoprotein phenotype in end stage renal failure : origin and extend of small dense low density lipoprotein formation. Am J Kidney Dis 2000 May ; 35(5) : 852-62.

{tab Corresponding Author}

Dr Sheela Kurian V

Professor of Medicine, Government Medical College, Kottayam, Kerala

{tabs}